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Abstract: This narrative review aims to summarize the current controversy on the balance 
between ethanol and phytochemicals in wine, focusing on light drinking and oral cancer. 
Extensive literature search included PUBMED and EMBASE databases to identify in human 
studies and systematic reviews (up to March 2015), which contributed to elucidate this  
issue. Independently from the type of beverage, meta-analyses considering light drinking  
(≤1 drinks/day or ≤12.5 g/day of ethanol) reported relative risks (RR) for oral, oro-pharyngeal, 
or upper aero-digestive tract cancers, ranging from 1.0 to 1.3. One meta-analysis measured 
the overall wine-specific RR, which corresponded to 2.1. Although little evidence exists on 
light wine intake, phytochemicals seem not to affect oral cancer risk, being probably present 
below the effective dosages and/or due to their low bioavailability. As expected, the risk of 
oral cancer, even in light drinking conditions, increases when associated with smoking habit 
and high-risk genotypes of alcohol and aldehyde dehydrogenases. 
Keywords: polyphenols; alcohol; risk factors; nutrition; oral squamous cell carcinoma; 
Mediterranean diet 
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1. Introduction 
In 2012, oral squamous cell carcinoma (OSCC) ranked as the 12th most common malignancy in Europe, 
affecting more than 73,000 European citizens of both sexes [1,2]. On what concerns mortality, stage of 
disease at diagnosis largely affects prognosis, with a five-year survival rate of 20% for advanced cases, 
corresponding to about 50% of OSCCs worldwide [3]. Prevention represents a major issue which is, 
currently, focused on avoiding tobacco smoking and reducing alcohol intake, the two most well-known 
risk factors for oral cancer [4]. 
In general, ethanol consumption, independently from the type of beverage, contemplates about 5%  
of all cancers, mainly of the liver [5], upper digestive and gastroenteric tracts, pancreas, breast,  
and lung [6–11]. In 2011, Western Europe had the 30% of oral cavity and pharynx cancers attributable 
to alcohol drinking [12], which raised to 44% for the upper aerodigestive tract cancers, i.e., localized  
at oral cavity, pharynx, larynx, and esophagus [13]. Oral cancer has been, thus, causally associated  
with ethanol intake, particularly when consumed above the recommended upper limits of two drinks  
a day (30 g of ethanol/day) in men, and one drink a day (15 g of ethanol/day) in women [13,14].  
These findings are indirectly supported by investigations on the role of alcohol-related cirrhosis not  
only as risk factor for hepatic cancer [5], but also for oral cancer, mainly in patients with potentially 
malignant oral disorders [15]. The increasing rate of liver cirrhosis, considered a surrogate marker of 
heavy ethanol intake, corresponded to growing incidence of oral cancer and related mortality [16].  
In 2014, the International Agency for Research on Cancer (IARC) published a monograph on  
the carcinogenic effect of ethanol in humans [17], which confirmed these previous epidemiological 
studies [12–14]. 
Although evidences demonstrated heavy drinking is a major risk factor for oral cancer [10], the effect 
of light wine consumption on the oral carcinogenesis is still under debate, taking into account the topical 
activity, towards the oral mucosa cells, of the two xenobiotics present in wine, i.e., ethanol and 
phytochemicals. Considering only the in-human studies, this review aims to analyze the putative roles 
of these wine components on oral cancer risk, focusing on the light drinking. Nonetheless, this survey 
also goes into moderate and heavy alcohol drinking as well, for comparison and for supporting the  
dose-dependent risk of disease and mortality. The authors independently carried out a comprehensive 
literature search on PUBMED and EMBASE databases, in order to identify systematic reviews and 
clinical studies on these issues, published in English, up to March 2015. 
2. Wine Drinking and General Health: A Brief Overview 
From the French paradox to date, a rising body of evidences reported health-promoting effects related to 
the habitual, low to moderate red wine intake at main meals [6,18]. Systematic reviews and meta-analyses 
supported, tough not unquestionably, that this nutritional habit may be protective against certain 
cardiovascular diseases, reducing morbidity and mortality rates [19,20]. The rationale is based on the high 
content of a variety of beneficial bioactive compounds, namely phytochemicals, contained in wine [21].  
On other hand, the heavy wine intake (at least more than three drinks/day) has been strongly associated 
with a dose-dependent risk of liver diseases, such as fatty liver, cirrhosis and hepatic carcinoma,  
certain types of cancer, and brain damage, mainly cognitive function impairment [5,22,23] (Figure 1). 
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Therefore, two cornerstones should be taken into account in patient risk analysis: (i) the individual 
drinking pattern; and (ii) the dietary habits. 
 
Figure 1. Model of alcohol consumption and health outcomes. 
2.1. Drinking Pattern 
The drinking pattern corresponds to the different “dimensions” of subject drinking and includes the 
type of beverage, as well as how much, when and how often an alcoholic beverage is consumed [24]. 
Three main drinking scenarios can be identified, apart from alcoholism disorders, i.e., abstention, low to 
moderate intake and heavy episodic drinking, the latter also called “binge” pattern. According to World 
Health Organization (WHO), the abstention group includes both “lifetime abstainers”, who have never 
consumed alcohol, and “former drinkers”, who previously consumed alcohol, but who did not in the  
last 12 months [25]. The heavy binge drinking group comprises mainly young subjects with an intake of 
at least 60 or more grams of pure ethanol (>5 drinks) on, at least, one occasion in the past seven days, 
generally during the weekend. In the middle, a regular and low to moderate consumption can be 
advocated: light alcohol intake, usually, corresponds up to one drink/day [26], while moderate 
consumption to one to two drinks/day [10]. The drinking pattern strongly affects health outcomes,  
at both short-term (acute) and long-term (chronic) level, with beneficial or harmful effects (Figure 1). 
Therefore, following a concept previously introduced for cardioprotection [21,27], the importance of 
drinking patterns was highlighted for oral cancer: in their epidemiological study, Petty and Scully 
suggested spirit drinkers usually consume high amount of alcohol in a unique occasion, with unbalanced 
high concentrations of ethanol over cancer-preventing phytochemicals [28]. Accordingly, the maximum 
oral cancer incidence and mortality are recorded in populations distributed in Eastern European 
countries, i.e., Hungary, Slovakia, and Romania, where the consumption of spirits is higher than other 
nations [2] (Table 1). Similarly, in Italian North-Eastern regions, where the daily intake of spirits,  
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in addition to wine, is a usual habit due to cultural traditions, the Italian highest percentage of oral cancer 
morbidity and mortality can be here observed [29]. These findings are also consistent with a recent study 
on Korean population, associating frequency of heavy binge drinking and mortality from oro-pharynx 
cancer [30]. However, further considerations on the association between individual alcohol abuse and 
general unhealthy behaviors are pivotal. Many reports suggest (un)healthy lifestyles tend to occur 
together, in particular the heavy binge alcohol drinking is associated with smoking habit, as well as to 
lower compliance to screening health programs [30]. 
Table 1. Recorded adult (15+) alcohol consumption by type of alcoholic beverage  
(in % of pure alcohol) in selected European and Mediterranean countries in 2005.  
Source: “European Status Report on Alcohol and Health”, WHO (World Health 
Organization) 2011 [31]. 
Country Spirits (%) Beer (%) Wine (%) Other 1 (%) 
Italy 5 22 73 0 
France 20 17 62 1 
Portugal 10 31 55 4 
Switzerland 18 31 50 1 
Greece 26 24 49 1 
Slovenia 13 39 48 0 
Sweden 17 39 44 0 
Hungary 2 24 35 40 1 
Denmark 16 45 39 0 
Morocco 13 50 37 0 
Belgium 6 57 37 <1 
Spain 13 45 36 6 
Tunisia 5 63 32 0 
United Kingdom 21 43 30 6 
Norway 20 47 31 2 
Germany 20 53 27 0 
Romania 2 39 39 22 0 
Slovakia 2 49 36 15 0 
Egypt 33 56 11 0 
Ukraine 61 32 7 <1 
Estonia 57 34 7 2 
Turkey 35 60 5 0 
Russian Federation 63 33 1 3 
1 Local traditional alcoholic beverages not included in the previous categories; 2 the top three European countries 
for the highest incidence and mortality rates of lip, oral cavity, and pharynx cancers are highlighted in bold. 
2.2. Dietary Habits 
Besides the importance of drinking patterns, a growing body of evidence supports dietary habits may 
affect the risk of developing oral cancer and, particularly, high fruit and vegetable consumption has been 
associated with a reduced risk of cancer [32]. The presence of hundreds of phytochemicals, also called 
nutraceuticals, in plant-derived foods, may exert health-promoting effects [30]. Nutritional habits 
Int. J. Mol. Sci. 2015, 16 17033 
 
 
including wine consumption, such as those belonging to the Mediterranean diet, may promote health 
benefits possibly due the synergistic effects between wine phytochemicals and nutraceuticals of fruit  
and vegetable [33,34]. Evidence correlated the adherence to this dietary style to a lower risk of  
overall cancers, including oral and pharyngeal ones [35–37]. Studies showed that the incidence and 
mortality rates for cancers of lip, oral cavity and pharynx decreased in Mediterranean countries,  
such as Italy, where red wine, in the context of a healthy diet, is commonly consumed [1,2] (Table 1). 
Accordingly, the “Mediterranean drinking pattern” has been emphasized, supporting as the relation 
between alcohol consumption and all-cause mortality follows a J-shaped curve, where the low and regular 
wine intake seems not to be harmful for health, possibly by virtue of phytochemical components [38]. 
3. Beneficial and Harmful Components of Wine 
The overall effects of wine drinking on health can be ascribed to the opposite role of phytochemicals 
and ethanol metabolites. 
3.1. Wine Phytochemicals 
Wine and grape polyphenols are phytochemicals belonging to phenylpropanoids, a large group of 
plant secondary metabolites derived from phenylalanine. They are divided into flavonoids (including 
anthocyanins), stilbenes (e.g., resveratrol) and proanthocyanidins (also called condensed tannins),  
and possess different molecular and biochemical targets both in healthy and damaged cells. 
The health-promoting effects of polyphenols can be ascribed to a number of in vitro activities,  
including antioxidant, antimicrobial, antiviral, anti-inflammatory and anticancer activities [28]. On the 
other hand, some concerns can arise from the heterogeneous content of polyphenols in food. Indeed,  
a recent study on wine grapes found a high variation in the phytochemical content of different  
cultivars [39], thus suggesting that phytochemical level would differ in wines produced in different 
geographical areas. 
Additional concerns are associated to preclinical evidences supporting many phytochemicals exert 
beneficial antioxidant effects when assumed in low to moderate doses, but can become prooxidant in 
case of high intake. Prooxidant activity can be beneficial against cancer cells, inducing apoptosis by 
production of toxic reactive oxygen species (ROS), but can become harmful if the oxidative stress 
damages healthy cells [28]. Thus far, there is no clinical study on the association of wine polyphenols 
and the risk of oral cancer, although a handful of studies, investigating phytochemicals and oral 
carcinogenesis, have been carried out on oral cancer cell lines and animal models. 
The health benefits of resveratrol, the most evocative red wine polyphenol, have been ascribed to its 
antioxidant, anti-inflammatory and anticancer properties, as well as to its effects on sirtuins, involved in 
the epigenetic regulation of ageing [20]. Preclinical studies on anticancer activity of resveratrol date 
back to almost two decades ago, when, in their seminal paper, Pezzuto and colleagues demonstrated its 
chemopreventive potential in vivo [40]. Few years later, Elattar and Virji reported similar results on oral 
cancer [41], then confirmed by other studies: In particular, the antiproliferative activity of red wine and 
its major components, resveratrol and quercetin, reduced the growth and DNA synthesis in human  
OSCC cells [42]. 
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In addition, new bioactive molecules have been recently discovered in grapes and wine, i.e., 
melatonin and phytosterols [20]. The former is an indoelamine traditionally considered a vertebrate 
neurohormone, while phytosterols include three main compounds, i.e., β-sitosterol, stigmasterol and 
campesterol, effective hypocholesterolizing agents. 
All these phytochemicals and, possibly, others still unknown, may synergistically maximize the 
healthy properties of wine. Interestingly, anticancer activity of grape juice, i.e., an assortment of wine 
phytochemicals without ethanol, was demonstrated by in vitro and in vivo models of tongue 
carcinogenesis [43]. However, the effective concentrations of these wine compounds are reported,  
in preclinical studies, at sub- to low-micromolar levels, which are at least one order of magnitude higher 
than those normally measured in human plasma after the oral intake of plant-derived foods, i.e., tens to 
hundreds nanomolar [44,45]. Consistently, clinical data on pharmacokinetics support the hypothesis  
that these dosages are difficulty achievable following a light to moderate drinking pattern: more than  
100 glasses of wine/day should be required to reach effective blood concentrations of resveratrol [46].  
This is more problematic even taking into account the inter-individual differences in polyphenol  
oral bioavailability. 
As a result, preclinical evidences regarding pharmacological activities of wine phytochemicals have 
not been fully substantiated by clinical trials and, besides the low oral availability of polyphenols,  
further factors, mainly ethanol and its metabolites, can counteract or nullify the protective effects of wine 
phytochemicals in human. Besides the methodological problems of in human studies, which, for instance, 
do not provide data on the active forms of phytochemicals, discrepancies between epidemiological and 
pre-clinical studies may also arise from the basic difference between the in vivo and in vitro action 
mechanisms of polyphenols [28]. As an example, the human metabolism of phytochemicals,  
involving their biotransformation by phase I and II enzymes, can alter their redox potential; this is 
confirmed by the lower antioxidant capacity of conjugates and metabolites over their aglycones [28]. 
3.2. Ethanol Metabolites 
The most commonly recognized carcinogenic compounds in alcoholic beverages are ethanol and its 
main metabolite, acetaldehyde, classified as Group 1 carcinogens (“carcinogenic to humans”) by  
IARC [17,47]. The IARC monograph reported their causal association with several cancers, including oral 
carcinoma [17]. A further wine component, which may play a detrimental role, has been identified in 
urethane (ethyl carbamate), classified as “probably carcinogenic to humans”, activating carcinogenetic 
pathways different than those of ethanol [17]. 
Even at low dosages, ethanol may enhance the risk of cancer in those sites, such as oral cavity,  
in direct contact with it, via acetaldehyde damage to DNA and production of ROS, thus decreasing the 
cell endogenous antioxidant pool [9]. Feller et al. supported the role of ethanol and acetaldehyde as 
carcinogens by analyzing preclinical studies on its prooxidant activity in saliva [48], although a further 
interventional study on healthy volunteers did not find significant outcomes of a glass of red wine on 
salivary antiradical capacity [49]. In addition, ethanol also activates other procarcinogens, as those 
contained in tobacco smoking, industrial effluents and environmental pollutants, increasing the 
permeability of mucosa epithelial layers, enhancing the solubilisation of xenobiotics and their entrance 
Int. J. Mol. Sci. 2015, 16 17035 
 
 
throughout oral mucosa, and activating the mono-oxygenase enzyme cytochrome P450 2E1 (CYP2E1) 
involved in xenobiotic biotransformation [17,50]. 
Genetic factors, related to reduced ethanol and acetaldehyde metabolism, further increase the risk of 
oral cancer. They mainly involve genes associated to the enzyme alcohol dehydrogenase (ADH),  
which oxidizes ethanol to acetaldehyde, which is further detoxified by the aldehyde dehydrogenase 2 
(ALDH2) to acetate, a less toxic compound. Genetic variants of these enzymes result in their low  
activity and decrease the clearance of ethanol and acetaldehyde from tissues. ALDH2 polymorphism, 
typically observable in East Asian subjects, correlates to high levels of acetaldehyde, in turn related to 
high risk of oral cancer [51–53]. In addition, endogenous salivary ADH is not the only responsible for 
the acetaldehyde production in the oral cavity: bacterial ADHs contribute to raise the salivary 
acetaldehyde levels and, consequently, may contribute to the epithelial cell proliferation [54,55]  
and DNA adduct formation [56]. Therefore, oral bacteria and, possibly, oral hygiene appear to play an 
additional pivotal role in ethanol metabolism. 
4. Wine Drinking and Oral Cancer Risk: The in Human Evidences 
In the attempt to identify a “cut-off dose” of ethanol for an increased risk of oral cancer,  
research revealed, in the past, a major drawback related to a not uniform way of reporting the total 
volume of individual ethanol intake. To overcome this issue, in recent years, standard units,  
namely “standard drinks” as g of ethanol/drink, have been proposed at supranational level to obtain a 
predictable relative risk, even if they are still not homogeneously accepted worldwide [57,58] (Table 2). 
Table 2. Definition of “standard drink” in different countries. Source: International Center 
for Alcohol Policies [57]. 
Standard Unit (in g of ethanol) Country 
8.0 United Kingdom 
9.9 Netherlands 
10.0 Australia, France, Hungary, Ireland, New Zealand, Poland, Spain 
11.0 Finland 
12.0 Denmark, Italy, South Africa 
13.6 Canada 
14.0 Portugal, United States 
On what concerns the type of beverage, wine-related data can be extrapolated from human trials on 
alcoholic beverage intake, particularly from systematic reviews, observational studies and biokinetic 
clinical trials on wine phytochemicals. The following paragraphs describe retrieved studies, also 
summarized in Table 3. 
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Table 3. Oral cancer risk and alcohol drinking. 
Reference Type of Article Wine * Oral Cancer Risk 
[11] Meta-analysis No Oral and pharyngeal cancer RR 1 = 5.13 for heavy drinkers. 
[59] Meta-analysis No 
Upper aero-digestive tract cancer: RR = 2.97 (but RR = 2.24 only  
considering oral cavity, pharynx, and larynx); alcohol intake  
increasing of 10 g/day equivalent to increasing RR of 1.09. 
[26] Meta-analysis Yes 
Wine-specific RR = 2.1 for any drinking pattern; RR = 4.92 for heavy 
drinking (≥4 drinks/day). 
[27] Meta-analysis No RR = 1.05 for light drinkers. 
[13] Meta-analysis No 25% Alcohol-attributable cases for upper aero-digestive tract cancer. 
[12] Meta-analysis No 
30% Alcohol-attributable cases for oral cavity and pharynx cancer  
with an increased risk related to 1 g/day of ethanol of 0.0185%. 
[26] Meta-analysis No 
RR = 1.3 for 10 g/day, 3.2 for 50 g/day, 8.6 for 100 g/day and 13.0 for 
125 g/day of ethanol. 
[60] Meta-analysis No RR = 1.1 for light drinkers; RR = 4.6 for heavy drinkers. 
[8] Meta-analysis No 
Oral cancer RR = 1.65 for 1–39 g/day of ethanol in men;  
RR = 1.43 for 1–19 g/day in women. 
[61] Meta-analysis No 
Oral cancer RRs = 1.86, 3.11 and 6.45 for ethanol intake of  
25, 50 and 100 g/day, respectively. 
[62] Meta-analysis No 
Oral cavity and pharynx cancers RRs = 1.75 (25 g/day of ethanol),  
2.85 (50 g/day), 6.01 (100 g/day). 
[63] Meta-analysis No 
Oral cancer RRs = 2.2, 4.2 and 10.7 for ethanol intake of 25, 50 and  
100 g/day, respectively. 
[64] 
Cohort study 
(Netherlands) 
No 
Oral cavity cancer: RRs = 1.25, 1.91, 3.88, 6.39 for 0–5, 5–15, 15–30, 
≥30 g/day of ethanol; for regular consumers: RRs = 1.65, 1.68, 3.20,  
7.50 in the same order; wine specific: RR = 1.07, 1.31, 0.93, for intake 
of 0–1, 1–2, ≥2 glasses/day. 
[30] Cohort study (Korea) No 
Daily binge drinkers versus non binge-drinkers: oropharyngeal cancer 
mortality HR 2 = 4.82; adjusting for the volume of alcohol intake and  
frequency of binge, HR = 4.90. 
[65] Case-control (Brazil) No 
Drinking was not independently associated with oral cancer;  
drinking status: ever drinker OR 3 = 4.21, level-1 drinker  
(≤862 g/year) OR = 1.68, level-2 drinker (>862 g/years) OR = 6.73;  
drinking and smoking status: never smoker and ever drinker OR = 0.58, 
ever smoker and ever drinker OR = 5.85. 
[4] 
Case-control ICARE 
study (France) 
No 
Population-attributable risk of oral cavity cancer 7.3% for  
alcohol drinking. 
[7] 
Case-control 
ARCAGE  
multi-centre study 
(10 European 
countries) 
No 
Oral cancer OR = 1.04 related to alcohol alone; OR = 7.06 related to  
alcohol/smoking joint effect. 
[66] 
Case-control  
(Turkey) 
Yes Oral cancer OR = 0.549 for red wine intake. 
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Table 3. Cont. 
Reference Type of Article Wine * Oral Cancer Risk 
[28] 
Ecological study 
(Europe,  
North America, 
Oceania and  
Far Eastern Asia) 
Yes 
Male age-standardised mortality rate for oral cancer: significantly  
increasing for every litre of pure ethanol (0.15 per 100,000 subjects)  
and spirits (0.26 per 100,000 subjects), but non-significant effects  
for beer and wine. 
[67] 
Case-control  
(4 European 
countries, Cuba, 
Canada, India, 
Sudan and Australia) 
Yes 
ORs = 2.86 for ever drinker, 2.12 for ex-drinkers, 3.46 for current  
drinkers; type of drink: only beer OR = 1.16, only wine and beer  
OR = 1.96, only wine OR = 2.71, spirits with or without wine or beer  
OR = 7.28; drinking amount (independently from type of beverage):  
for 1 drink/day OR = 2.00, for 2 drinks/day OR = 3.74, for 3–4 drink/day,  
OR = 6.22, for 5–6 drink/day OR = 10.58, for 7–10 drink/day OR = 10.29. 
[68] 
Case-control  
(Italy and 
Switzerland) 
Yes Wine, OR = 1.0 for 1–2 drinks/day, 2.2 for ≥3 drinks/day. 
[69] 
Case-control  
(Southern Greece) 
Yes 
OR = 1.7 for moderate drinkers (1–28 drinks/week); ORs = 0.8  
and 1.1 only considering wine drinkers of 1 drinks/week and  
≥14 drinks/week, respectively. 
[70] 
Case-control  
(Spain) 
Yes 
OR = 1.89 for 1–50 g/day of alcohol; OR = 5.3 in wine drinkers 
exceeding 50 g/day of ethanol (i.e., 4 glasses per day). 
[6] 
Cohort study 
(Denmark) 
Yes 
RR = 3.0 for drinkers of 7–21 beers or spirits/week, but not wine, 
compared with non-drinkers; RR = 0.5 for subjects with the same  
total alcohol intake, but with wine (>30% of their intake); RR = 5.2  
for drinkers of >21 beers and spirits/week but not wine, RR = 1.7  
for subjects with the same total alcohol intake, but including wine. 
[71] 
Case-control  
(Japan) 
No 
OR = 3.6, 4.5 and 4.8 for sake, beer and hard liquor drinkers, 
respectively. 
[72] 
Case-control  
(Italy) 
Yes 
OR = 11.2, 9.9 and 4.1 among heavy drinkers (≥84 drinks/week) of wine 
only, wine and spirits and combination wine-spirits-beer. 
[73] 
Case-control  
(North Italy) 
Yes 
OR = 4.9 for heavy wine drinkers (≥56 glasses/week, i.e., about 1 litre/day), 
rising to 8.5 for drinkers of ≥84 glasses/week. 
[49] 
Salivary biokinetics 
(Caucasoid  
healthy subjects) 
Yes 
Acute intake of 125 mL of red wine: no effect on anti-radical salivary 
capacity, but administration of red wine polyphenol capsules improved 
the salivary antioxidant status. 
[52] 
Salivary and blood 
biokinetics (Asian 
healthy subjects) 
Yes 
Acute intake of 0.6 g ethanol/kg body weight in the form of 13% ethanol 
Calvados, 13% ethanol shochu, 13% ethanol red wine and 5% ethanol beer. 
[74] 
Salivary and blood 
biokinetics  
(Asian heavy  
drinkers-alcoholics) 
No 
Patients with homozygous alcohol dehydrogenase-1B (ADH1B*1/*1), 
who drunk the day before, were associated with higher levels of ethanol 
persisting in the blood for longer periods and had higher salivary 
acetaldehyde levels, correlating to oral bacteria and yeast counts;  
no effect of inactive heterozygous aldehyde dehydrogenase-2 
(ALDH2*1/*2) was observed on ethanol lingering the next morning. 
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Table 3. Cont. 
Reference Type of Article Wine * Oral Cancer Risk 
[75] 
Salivary and  
blood biokinetics  
(Asian healthy subjects) 
No 
Acute intake of 0.4 g ethanol/kg body weight in a standardized 
10% (v/v) solution of absolute ethanol in orange juice (with and 
without previous ingestion of 4-methylpyrazole, an inhibitor of 
human ADH): a high salivary production of acetaldehyde by oral 
microflora alcohol dehydrogenase was observed. 
[55] 
Salivary and blood 
biokinetics (Asian and 
Caucasoid healthy subjects) 
No 
Acute intake of 0.5 g ethanol/kg body weight in a standardized 
10% (v/v) solution of absolute ethanol in orange juice: Aldehyde 
dehydrogenase-2 (ALDH2) deficient subjects had 2–3 times 
higher salivary acetaldehyde levels than ones with normal 
ALDH2, after 240 min; salivary acetaldehyde originated from 
oral microflora and parotid gland ethanol metabolism. 
[54] 
Salivary and blood 
biokinetics/cohort  
study (Finland, healthy 
subjects, dental and oral 
cancer patients, heavy 
drinkers—alcoholics) 
No 
Smoking and heavy alcohol intake increased salivary 
acetaldehyde; considering alcoholic status, levels of 
acetaldehyde were: teetotalers 111 μmol/L, moderate alcohol 
consumption 104 μmol/L, heavy drinkers 172 μmol/L. 
[76] 
Salivary and  
blood biokinetics  
(Caucasoid healthy subjects) 
No 
Acute intake of 0.5 g ethanol/kg body weight in a standardized 
10% (v/v) solution of absolute ethanol in orange juice; salivary 
acetaldehyde was associated with oral microflora: it peaked 
within 40 min after ethanol ingestion and decreased after a  
3-day use of antiseptic mouthwash (chlorhexidine). 
* Wine-specific analysis of data for oral cancer risk; 1 RR, relative risk; 2 HR, hazard ratio; 3 OR, odd ratio. 
4.1. Systematic Reviews 
Recent meta-analyses have causally correlated oral cavity cancer to alcohol consumption over 
recommended doses, reporting the 25% and 44% of cancer cases attributable to ethanol in woman and 
man, respectively, although these data are only based on case-control studies [61,63]. In 1999, the relative 
risk (RR) of oral cancer for subjects drinking 25 g of ethanol/day (two drinks/day) was 2.2 and followed 
a dose-dependent increase [63], also confirmed by recent studies [59,76]. In 2004, when more studies 
became available, the RR changed to 1.86 for the same ethanol consumption [61], decreased to 1.2 for 
the intake of ≤1 drink/day [62], whereas raised to 5.2 for heavy alcohol drinkers (≥4 drinks/day) [77]. 
Consistently, in 2006, the RRs of oral cancer corresponded to 1.65 in men with an overall intake of  
1–39 g of ethanol/day, and to 1.43 in women with the same ethanol intake [9]. 
Considering data only on light and regular alcohol consumption, a recent meta-analysis suggested a 
RR of oral cancer corresponding to 1.05, independently from the type of beverage [10], even weaker in 
never/non-current smokers [26,78]. Further estimations of RRs for light drinkers, in comparison to 
abstainers or occasional alcohol consumers, were 1.1 for oral cancers, 1.2 for pharyngeal cancers [26] 
and 1.26 for upper aero-digestive tract cancers [59,76]. As regards type of beverage, overall RRs for any 
drinking pattern and independently from smoking status, corresponded to 2.1, 2.4, and 2.3 for wine-,  
beer- and spirits-only intakes, respectively [26]. Heavy drinkers showed RRs equal to 4.9, 4.2, and 5.2, 
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following the same order of beverages, whereas results on light to moderate drinking were not recorded 
because of limited data availability [26]. 
4.2. Observational Studies 
The most prevalent alcoholic beverage in a given population is commonly the most heavily  
consumed one, in turn most likely to be associated with increased oral cancer risk [6,13,79].  
For instance, in the Italian population, heavy drinking of wine, the predominant beverage consumed, 
appeared to produce the highest threat when compared with similar intake of beer and spirit [72,73,79]. 
As expected, the risk increased in a dose-dependent trend [64,67,68,70,73], corroborating the  
importance of the drinking pattern. In 2014, a Korean study associating heavy binge drinking and  
oro-pharynx cancer mortality showed a hazard ratio (HR) of 4.90, whereas the latter was 1.50 for  
non-binge drinkers [30]. Petty and Scully reported mortality rate for oral cancer significantly increased 
for every litre of pure ethanol (0.15 per 100,000 subjects) and spirits (0.26 per 100,000 subjects),  
though without significant effects for beer and wine [28]. Similarly, a case-control study carried out in 
Italy and Switzerland demonstrated that, compared to abstainers or light drinkers, overall odds ratio (OR) 
for oral cancer was 2.1 for three to four drinks/day, decreasing to 1.0 for one to two drinks/day of  
wine [68]. These data are consistent with studies performed on Turkish [66], Greek [69] and Japanese 
populations [71], reporting higher risk associated to liquor consumers than wine drinkers. A Spanish 
case-control study also reported increased risk of oral cavity or oropharynx cancers among individuals 
drinking 1 drink per day (overall OR = 2.0), which was higher for spirit consumers than wine drinkers 
(OR of 7.2 and 2.7, respectively) [67]. Finally, the Netherlands Cohort Study found a RR for oral cancer 
of 1.68 for “stable” drinkers of 5–15 g ethanol/day (people who did not change the habit in the last  
five years); interestingly, the only wine consumption of 0–1 or 1–2 glasses/day gave RRs of 1.07  
and 1.31, respectively [64]. 
Considering the combined effect of tobacco and ethanol, strong evidence correlated high levels of 
alcoholic beverage consumption to heavy smoking habit [73]. This dose-dependent and synergistic effect 
was confirmed in the large French ICARE study, showing the 81% of oral cancer risk attributable to 
tobacco and ethanol exposures, with smoking responsible for the higher risk [32,80]. These findings  
are consistent with the European ARCAGE case-control study: oral cancer OR was 1.04 related to alcohol 
alone and increased to 7.06 in presence of combined ethanol and tobacco use [7,70,81]. 
Tobacco smoking is the main risk factor for the majority of SCC of the oral cavity. When studying 
the role of alcohol in oral carcinogenesis, it is necessary to adjust for tobacco use and, more importantly, 
to conduct the study on never smokers. As reported above, many epidemiologic studies focused on  
the association between alcohol intake and oral cancer risk, and most have adjusted for tobacco use; 
conversely, a number of studies investigated the influence of alcohol on oral cancer risk among never users 
of tobacco. In the study from INHANCE (International Head and Neck Cancer Epidemiology Consortium), 
the association between ethanol intake (from light to heavy: 0, <1, 1–2, 3–4, >5 drinks/day) and the risk 
of head and neck (oral cavity, oropharynx and larynx) cancers among never users of tobacco was 
examined [32,80]. However, some observational studies, which do not take into account a number of 
confounding factors, need to be carefully interpreted, in order to avoid the potential overestimation of 
smoking and drinking independent roles. After adjustment for age, sex and instruction in multivariable 
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analyses, drinking seems not to be an independent risk factor for oral cancer [65]. To further complicate 
the interpretation of the results, important publication biases should be considered: they include drinker’s 
under-reporting of alcohol consumption [82] or frequent incorrect categorization of former drinkers into 
non-drinker group [10]. 
4.3. Biokinetics Studies 
Low oral bioavailability and poor systemic delivery to target tissues and organs represent  
the major drawbacks associated with the clinical failure of many promising phytochemicals [83].  
Pharmacokinetic studies on resveratrol, quercetin and anthocyanidines were carried out in healthy 
volunteers after grape juice and moderate red wine consumptions: results showed that glycosides,  
mainly glucose conjugates, are absorbed to a lesser extent than the corresponding aglycones [82,84]. 
Within the oral cavity, hydrolysis of anthocyanidines, quercetin and genistein glucosides to their aglycones 
by salivary, bacterial and cellular β-glucosidases was demonstrated, with a remarkable inter-individual 
variability [42]. Similarly to small intestine, phase II and efflux transporting enzymes are also present in 
human oral mucosa, as well as glucuronidated anthocyanin conjugates, can be detected in saliva [42]. 
Oral cavity tissues are in direct contact with wine and related bioactive phytochemicals. Hence, the levels 
of salivary polyphenols peaked soon after red wine intake in healthy volunteers and appeared to derive 
mainly from a reservoir adhering to oral mucosa, rather than from systemic absorption [85,86]. 
Besides studies on polyphenol biokinetics in oral fluids, many investigations focused on the analysis 
of salivary acetaldehyde. Apart from the systemic ethanol metabolism, a 30 second rinsing of the oral 
cavity with different alcoholic beverages, including wine, increased the salivary acetaldehyde levels  
over the threshold previously shown to be carcinogenic by in vitro models [85]. However, a cross-over 
randomized clinical trial on Japanese volunteers, focusing on wine intake, reported that the salivary 
concentration of acetaldehyde was lower soon after drinking a glass of 13% wine in comparison to other 
alcoholic beverages [52]. A further element affecting salivary acetaldehyde is the smoking habit, since 
smokers showed higher level of this compound, probably related to oral bacteria metabolism [54]. 
Finally, high-risk genotypes of salivary alcohol and aldehyde dehydrogenases, i.e., ADH1B  
and ALDH2, respectively, commonly reported in certain Asian populations, significantly affected 
acetaldehyde levels in saliva [55,74,81]. Thus, the high salivary acetaldehyde production in these 
drinkers represents a plausible explanation for the enhanced cancer risk observed, partly attributable to 
prolonged ethanol and acetaldehyde exposures because of the less-active ADH1B and ALDH2 enzymes, 
as well as to oral microflora over-growth [55,75,86]. Noteworthy, many epidemiological studies showed 
the ALDH2 deficiency gene (ALDH2*2 allele) to be associated with markedly increased risk of digestive 
tract cancers, including oro-pharyngeal cancers, even after a moderate dose of alcohol intake [55,86].  
In particular, it has been suggested that individuals with normal ALDH2 need to drink about two to three 
times more alcohol per occasion to achieve the same salivary acetaldehyde levels of subjects with the 
deficient isoenzyme [55,86]. 
  
Int. J. Mol. Sci. 2015, 16 17041 
 
 
5. Conclusions 
Drinking pattern, dietary habit and type of population under investigation can affect the cancer risk. 
Although little evidence exists specifically focusing on light wine intake, a low, but present, risk of oral 
cavity cancer can be observed. 
Phytochemicals in wine seem not to have any influence on cancer risk, possibly because they are 
present at low levels and poorly absorbed, reaching in human levels much below the effective 
concentrations assessed in preclinical studies. Therefore, currently, there is clearly not a causal 
correlation between phytochemicals in wine and health outcomes, as well as it appears premature to 
assume that phytochemical and ethanol, in this beverage, play a balancing role on oral carcinogenesis, 
with the former being protective and the latter being harmful. 
Noteworthy, when ethanol consumption is coupled to smoking habit or to high-risk dehydrogenase 
genotypes, the oral cancer risk dramatically increases. The clinician should always assess the  
patient-specific risk, considering the additive/synergistic behaviors, including drinking pattern, dietary 
habits and smoking status together. 
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